Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,181.2
-58.8 (-1.81%)

 

  • STI Straits Times Index
    3,181.2
    -58.8 (-1.81%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,551.6
    -21.2 (-1.35%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    27,940.5
    -
    Index delayed 15 minutes
  • SSE SSE Composite Index
    2,976.5
    -84.2 (-2.75%)
    Index delayed 15 minutes
  • N225 Nikkei 225
    23,215.7
    -127.8 (-0.55%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    6,111.2
    -22.0 (-0.36%)
    Index delayed 10 minutes
  • KOR KOSPI
    2,176.7
    -69.4 (-3.09%)
    Index delayed 20 minutes
  • XAO XAO
    7,098.4
    -104.8 (-1.45%)
     

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 2,422.8M
  • Value: 2,070.9M
  • Rise: 59
  • Fall: 358
  • Unch: 399

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
Medtecs Intl0.172+0.068
CWX Global0.004-
Healthway Med0.046+0.007
Genting Sing0.875-0.035
AsiaMedic0.017+0.002
Singtel3.360-0.030
Rex Intl0.168-0.013
AusGroup^0.037-0.005
YZJ Shipbldg SGD0.985-0.055
Spackman0.017-0.001

World Indices

World Indices
Name Last Change
Nasdaq 9,139.3 -175.6
HSI 27,940.5
HSCEI 10,969.3
Jakarta 6,111.2 -22.0
Nikkei 225 23,215.7 -127.8
SSE Comp 2,976.5 -84.2
Shanghai A 3,118.9 -88.2
Shanghai B 248.6 -8.9
PSE Comp 0.0
KOSPI 2,176.7 -69.4

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

Lonza LONZA GROUP LTD
Quotes 10 Minutes Delayed. Updated at 28 Jan 2020 07:12
Last (SGD): 79.970 Change: - High: - Remarks: -
Change (%): - Low: -
Open - Yesterday's Close 79.970
Buy Price - Sell Price -
Buy Volume ('000) - Sell Volume ('000) -
Cumulative Volume ('000) - Cumulative Value -
Click to show Stock Prices chart

Key Statistics

EPS (SGD) a 12.09277 Trailing EPS (SGD) e 12.09277 NAV (SGD) b 121.7527
PE a 6.613 Trailing PE f 6.613 Price / NAV b 0.6568
Dividend (SGD) d 3.828000 Cash In Hand (SGD) g 9.4680 Issued & Paid-up Shares c 74,246,000
Dividend Yield (%) d 4.787 Price / Cash In Hand g 8.446 Treasury Shares h 223,000
Beta - 75 Daysi - R-Squared - 75 Days(%)i - Market Cap (M) 5,937.453
Beta - 500 Daysi - R-Squared - 500 Days (%)i - Enterprise Value (M) 10,261.005
Piotroski F Score 8 Exchange Code O6Z Par Value ( CHF ) 1.00000
52 Weeks Volatility (%) 0.0 6-Month VWAP n.a. Free Float (%) 99.8
Under CPF Investment Scheme (CPFIS) No
Sector & Industry Manufacturing - Biotechnology
Category Classification Foreign Listing (Others) / Medical & Biotechnology
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. Updated on 08 Mar 2019.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand. Updated on 08 Mar 2019.
  9. Beta and R-Squared are calculated in relation to the market index (STI or KLCI) using the historical daily closing values of the stock and index as data points.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference Lonza SGX 5,937.453 6.613 6.613 0.6568 4.787
Industry Biotechnology SGX 1,987.662 6.375 6.756 0.6574 4.766
Foreign Listing (Others) SGX 7,155.101 14.942 14.905 1.6013 3.188
Medical & Biotechnology SGX 1,061.869 21.765 20.567 1.4107 1.820
Local Peer Suntar Eco-City^ SGX 18.828 - - 1.1312 -
Local Peer QT Vascular SGX 6.706 0.167 - 0.4478 -
Global Peer AMGEN INC NASDAQ 132,473.323 15.782 16.422 12.1235 2.509
Global Peer CSL ASX 141,910.746 52.894 52.894 18.9640 0.849
Global Peer GILEAD SCIENCES INC NASDAQ 80,754.524 14.804 29.987 3.9194 3.620
Global Peer AMGEN-T HKEx 594,184.000 9.032 9.399 6.9364 4.385
Global Peer VERTEX PHARMACEUTICAL NASDAQ 58,468.196 27.890 27.274 11.1296 -
Global Peer BIOGEN INC NASDAQ 50,729.464 11.450 9.402 3.6246 -
Global Peer ILLUMINA INC NASDAQ 46,146.240 55.867 47.427 10.3956 -
Global Peer REGENERON PHARMACEUTICALS INC NASDAQ 37,266.948 15.246 17.380 3.5477 -
Global Peer AGILENT TECHNOLOGIES INC NYSE 26,849.440 84.967 25.070 5.6549 0.706
Global Peer ALEXION PHARMACEUTICAL INC NASDAQ 23,301.942 300.282 15.848 2.2477 -
Other Global Peers SEATTLE GENETICS INC (NASDAQ), SINO BIOPHARM (HKEx), WUXI BIO (HKEx), INCYTE CORPORATION (NASDAQ), BIOMARIN PHARMACEUTICAL (NASDAQ), GALAPAGOS NV SPON ADR REPR 1 ORD SHS (NASDAQ), ALNYLAM PHARMACEUTICALS INC (NASDAQ), BEIGENE (HKEx), EXACT SCIENCES CORP (NASDAQ), BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS (NASDAQ), 10X GENOMICS INC (NASDAQ), NEUROCRINE BIOSCIENCES INC (NASDAQ), SAREPTA THERAPEUTICS INC (NASDAQ), IONIS PHARMACEUTICALS INC (NASDAQ), BIO-TECHNE CORP (NASDAQ), MODERNA INC (NASDAQ), BIONTECH SE SPON ADS EACH REP 1 ORD SHS (NASDAQ), ASCENDIS PHARMA A/S SPON ADR EACH REP 1 ORD SHS (NASDAQ), ACADIA PHARMACEUTICALS INC (NASDAQ), EXELIXIS INC (NASDAQ), REPLIGEN CORP (NASDAQ), BLUEBIRD BIO INC (NASDAQ), ARROWHEAD PHARMACEUTICALS INC (NASDAQ), CHINA BIOLOGIC PRODUCTS HLDGS INC (NASDAQ), GENSCRIPT BIO (HKEx), GLOBAL BLOOD THERAPEUTICS INC (NASDAQ), MORPHOSYS SPON ADS EACH REP 0.25 ORD SHS (NASDAQ), ZAI LAB LIMITED ADS EACH REP 1 ORD SHS (NASDAQ), MIRATI THERAPEUTICS INC (NASDAQ), IMMUNOMEDICS INC (NASDAQ), FIBROGEN INC (NASDAQ), 3SBIO (HKEx), AGIOS PHARMACEUTICALS INC (NASDAQ), BLUEPRINT MEDICINES CORP (NASDAQ), NEKTAR THERAPEUTICS (NASDAQ), DECIPHERA PHARMACEUTICALS INC (NASDAQ), MOMENTA PHARMACEUTICALS INC (NASDAQ), ULTRAGENYX PHARMACEUTICAL INC (NASDAQ), CRISPR THERAPEUTICS AG (NASDAQ), PTC THERAPEUTICS INC (NASDAQ), ACCELERON PHARMA (NASDAQ), EMERGENT BIOSOLUTIONS INC (NYSE), ALLOGENE THERAPEUTICS INC (NASDAQ), KODIAK SCIENCES INC (NASDAQ), NATERA INC (NASDAQ), IOVANCE BIOTHERAPEUTICS INC (NASDAQ), VIR BIOTECHNOLOGY INC (NASDAQ), ALKERMES PLC (NASDAQ), DENALI THERAPEUTICS INC (NASDAQ), UNIQURE N.V. (NASDAQ), HALOZYME THERAPEUTICS INC (NASDAQ), CHEMOCENTRYX INC (NASDAQ), AMICUS THERAPEUTICS INC (NASDAQ), ARENA PHARMACEUTICALS INC (NASDAQ), VIELA BIO INC (NASDAQ), MYRIAD GENETICS INC (NASDAQ), HERON THERAPEUTICS INC (NASDAQ), EIDOS THERAPEUTICS INC (NASDAQ), AIMMUNE THERAPEUTICS INC (NASDAQ), ARVINAS INC (NASDAQ), AURINIA PHARMACEUTICALS INC (NASDAQ), EPIZYME INC (NASDAQ), XENCOR INC (NASDAQ), FATE THERAPEUTICS (NASDAQ), ALECTOR INC (NASDAQ), INSMED INC (NASDAQ), ALPHAMAB-B (HKEx), REGENXBIO INC (NASDAQ), HAOHAI BIOTEC (HKEx), INTRA-CELLUAR THERAPIES INC (NASDAQ), LIGAND PHARMACEUTICAL INC (NASDAQ), CORTEXYME INC (NASDAQ), EDITAS MEDICINE INC (NASDAQ), ESPERION THERAPEUTICS INC (NASDAQ), VERACYTE INC (NASDAQ), COHERUS BIOSCIENCES INC (NASDAQ), TG THERAPEUTICS INC (NASDAQ), DICERNA PHARMACEUTICALS INC. (NASDAQ), POLYNOVO LIMITED (ASX), ROCKET PHARMACEUTICALS INC (NASDAQ), NEXTCURE INC (NASDAQ), NGM BIOPHARMACEUTICALS INC (NASDAQ), MYOVANT SCIENCES LTD (NYSE), MESOBLAST LTD (ASX), FRONTAGE (HKEx), MESOBLAST LTD SPON ADR EACH REP 5 SHS (NASDAQ), CKLIFE SCIENCES (HKEx), RAPT THERAPEUTICS INC (NASDAQ), ENANTA PHARMACEUTICALS INC (NASDAQ), OPKO HEALTH INC (NASDAQ), LUMINEX CORP(DEL) (NASDAQ), DBV TECHNOLOGIES SPON ADR EACH REPR 0.5 ORD (NASDAQ), DERMIRA INC (NASDAQ), KARYOPHARM THERAPEUTICS INC (NASDAQ), NANOVIRICIDES INC (NYSE American), NANOSTRING TECHNOLOGIES INC (NASDAQ), AVITA MEDICAL LTD (ASX), XBIOTECH INC (NASDAQ), AVITA MEDICAL LTD SPON ADS EACH REP 20 ORD SHS (NASDAQ), ACHILLION PHARMACEUTICALS INC (NASDAQ), APPLIED THERAPEUTICS INC (NASDAQ), AKEBIA THERAPEUTICS INC (NASDAQ), VIVA BIOTECH (HKEx), RADIUS HEALTH INC (NASDAQ), INTREXON CORP (NASDAQ), SANGAMO THERAPEUTICS INC (NASDAQ), IMMUNOGEN INC (NASDAQ), ZIOPHARM ONCOLOGY INC (NASDAQ), RHYTHM PHARMACEUTICALS INC (NASDAQ), STOKE THERAPEUTICS INC (NASDAQ), TWIST BIOSCIENCE CORPORATION (NASDAQ), CARA THERAPEUTICS INC (NASDAQ), PACIFIC BIOSCIENCES CALIFORNIA INC (NASDAQ), ATARA BIOTHERAPEUTICS INC (NASDAQ), VANDA PHARMACE INC (NASDAQ), OMEROS CORP (NASDAQ), ADVERUM BIOTECHNOLOGIES INC (NASDAQ), CYTOKINETICS INC (NASDAQ), ASCENTAGE-B (HKEx), GENFIT SPON ADS EACH REP 1 ORD SHS (NASDAQ), CELLECTIS ADS EACH REPR 1 ORD SPON (NASDAQ), RETROPHIN INC (NASDAQ), KADMON HLDGS INC (NYSE), HOMOLOGY MEDICINES INC (NASDAQ), FREQUENCY THERAPEUTICS INC (NASDAQ), FLEXION THERAPEUTICS INC (NASDAQ), INTELLIA THERAPEUTICS INC (NASDAQ), SORRENTO THERAPEUTICS INC (NASDAQ), MEIRAGTX HOLDINGS PLC (NASDAQ), RUBIUS THERAPEUTICS INC (NASDAQ), ARDELYX INC (NASDAQ), AVROBIO INC (NASDAQ), CLOVIS ONCOLOGY INC (NASDAQ), PREVAIL THERAPEUTICS INC (NASDAQ), NANTKWEST INC (NASDAQ), REPLIMUNE GROUP INC (NASDAQ), MORPHIC HOLDING INC (NASDAQ), MOLECULAR TEMPLATES INC (NASDAQ), UROGEN PHARMA LTD (NASDAQ), INNATE PHARMA SPON ADS EACH REP 1 ORD SHS (NASDAQ), MAGENTA THERAPEUTICS INC (NASDAQ), AUTOLUS THERAPEUTICS PLC SPON ADS EA REP 1 ORD SHS (NASDAQ), KURA ONCOLOGY INC (NASDAQ), PROTHENA CORP PLC (NASDAQ), SINOMAB BIO-B (HKEx), AGENUS INC (NASDAQ), MACROGENICS INC (NASDAQ), MERUS B V (NASDAQ), BIOCRYST PHARMACEUTICALS INC (NASDAQ), MERIDIAN BIOSCIENCE INC COM (NASDAQ), PRECISION BIOSCIENCES INC (NASDAQ), BELLUS HEALTH INC (NASDAQ), TRANSLATE BIO INC (NASDAQ), ADAPTIMMUNE THERAPEUTICS PLC ADS EACH REPR 6 SHS (SPONS) (NASDAQ), SINOVAC BIOTECH LTD (NASDAQ), VIKING THERAPEUTICS INC (NASDAQ), XENON PHARMACEUTICALS INC (NASDAQ), DYNAVAX TECHNOLOGIES CORP (NASDAQ), ARCUS BIOSCIENCES INC (NYSE), VOYAGER THERAPEUTICS INC (NASDAQ), APTOSE BIOSCIENCES INC (NASDAQ), COMPUGEN (NASDAQ), CORBUS PHARMACEUTICALS HOLDINGS IN (NASDAQ), ASCLETIS-B (HKEx), CABALETTA BIO INC (NASDAQ), ESSEX BIO-TECH (HKEx), RIGEL PHARMACEUTICALS INC (NASDAQ), PROGENICS PHARMACEUTICALS INC (NASDAQ), PROQR THERAPEUTICS N V (NASDAQ), ANAPTYSBIO INC (NASDAQ), AVID BIOSERVICES INC (NASDAQ), PDL BIOPHARMA INC (NASDAQ), CALITHERA BIOSCIENCES INC (NASDAQ), MERSANA THERAPEUTICS INC (NASDAQ), HARPOON THERAPEUTICS INC (NASDAQ), RECRO PHARMA INC (NASDAQ), CUE BIOPHARMA INC (NASDAQ), LEXICON PHARMACEUTICALS INC (NASDAQ), IVERIC BIO INC (NASDAQ), PERSONALIS INC (NASDAQ), LEE'S PHARM (HKEx), MANNKIND CORPORATION (NASDAQ), NEUROINSIGHTS NEUROTECH (NASDAQ), CELLULAR BIOMEDICINE GROUP INC (NASDAQ), CYTOMX THERAPEUTICS INC (NASDAQ), STEMLINE THERAPEUTICS INC (NASDAQ), EIGER BIOPHARMACEUTICALS INC (NASDAQ), BIOXCEL THERAPEUTICS INC (NASDAQ), PUMA BIOTECHNOLOGY INC (NASDAQ), SYROS PHARMACEUTICALS INC (NASDAQ), UNITY BIOTECHNOLOGY INC (NASDAQ), TRILLIUM THERAPEUTICS INC (NASDAQ), DPHARMA (Bursa), SCHOLAR ROCK HOLDING CORPORATION (NASDAQ), CASI PHARMACEUTICALS INC (NASDAQ), NEXT SCIENCE LTD (ASX), NOVAVAX INC (NASDAQ), PFENEX INC (NYSE American), GERON CORP (NASDAQ), MEDICINOVA INC (NASDAQ), SPECTRUM PHARMACEUTICALS INC (NASDAQ), KAMADA (NASDAQ), TELIX PHARMACEUTIC (ASX), WAVE LIFE SCIENCES LTD (NASDAQ), ADMA BIOLOGICS INC (NASDAQ), BIOFRONTERA AG SPON ADS EACH REP TWO ORD SHS (NASDAQ), NEPTUNE WELLNESS SOLUTIONS INC (NASDAQ), EVOFEM BIOSCIENCES INC (NASDAQ), VBI VACCINES INC CDA (NASDAQ), BBI LIFE SCI (HKEx), CONCERT PHARMACEUTICALS INC (NASDAQ), LIMINAL BIOSCIENCES INC (NASDAQ), SERES THERAPEUTICS (NASDAQ), JOUNCE THERAPEUTICS INC (NASDAQ), ATHERSYS INC (NASDAQ), NAVIDEA BIOPHARMACEUTICALS INC (NYSE American), IMV INC (NASDAQ), AFFIMED N V (NASDAQ), REDHILL BIOPHARMA LTD SPON ADS EA REPR 10 ORD ILS0.00 (NASDAQ), XOMA CORP (NASDAQ), NEUREN PHARMACEUTICALS LTD (ASX), BICYCLE THERAPEUTICS PLC SPON ADS EACH REP 1 ORD SHS (NASDAQ), LA JOLLA PHARMACEUTICAL CO (NASDAQ), FIVE PRIME THERAPEUTICS (NASDAQ), CHIASMA INC (NASDAQ), PROTAGONIST THERAPEUTICS INC (NASDAQ), TAIWAN LIPOSOME COMPANY LTD SPON ADS EACH REP 2 ORD SHS (NASDAQ), SYNDAX PHARMACEUTICALS INC (NASDAQ), GLYCOMIMETICS INC (NASDAQ), ARBUTUS BIOPHARMA CORP (NASDAQ), MONOPAR THERAPEUTICS INC (NASDAQ), NUCANA PLC SPON ADR EACH REP 1 ORD SHS (NASDAQ), FORTRESS BIOTECH INC (NASDAQ), DYADIC INTERNATIONAL INC (NASDAQ), PIERIS PHARMACEUTICALS INC (NASDAQ), LINEAGE CELL THERAPEUTICS INC (NYSE American), ANAVEX LIFE SCIENCES CORPORATION (NASDAQ), ALDEYRA THERAPEUTICS (NASDAQ), ELOXX PHARMACEUTICALS INC (NASDAQ), STRONGBRIDGE BIOPHARMA PLC (NASDAQ), SOLID BIOSCIENCES INC (NASDAQ), ARAVIVE INC (NASDAQ), GALECTIN THERAPEUTICS INC (NASDAQ), CONTRAFECT CORP (NASDAQ), X4 PHARMACEUTICALS INC (NASDAQ), CIDARA THERAPEUTICS INC (NASDAQ), APPLIED GENETIC TECHNOLOGIES CORP (NASDAQ), SELECTA BIOSCIENCES INC (NASDAQ), MATINAS BIOPHARMA HOLDINGS INC (NYSE American), VERASTEM INC (NASDAQ), CYMABAY THERAPEUTICS INC (NASDAQ), NEUROBO PHARMACEUTICALS INC (NASDAQ), NABRIVA THERAPEUTICS PLC (NASDAQ), SAVARA INC (NASDAQ), ERYTECH PHARMA SPON ADR EACH REPR 1 ORD (NASDAQ), UNI-BIO GROUP (HKEx), VTV THERAPEUTICS INC (NASDAQ), RESAPP HEALTH LIMITED (ASX), CEL-SCI CORP (NYSE American), PYC THERAPEUTICS LIMITED (ASX), AXCELLA HEALTH INC (NASDAQ), FENNEC PHARMACEUTICALS INC (NASDAQ), ENZO BIOCHEM INC (NYSE), EDAP TMS S.A. SPON ADR EACH REPR 1 ORD SHARE (NASDAQ), HARVARD BIOSCIENCE INC (NASDAQ), PARATEK PHARMACEUTICALS INC (NASDAQ), AVALON GLOBOCARE CORP (NASDAQ), VACCINEX INC (NASDAQ), CHIMERIX INC (NASDAQ), ADURO BIOTECH INC (NASDAQ), 22ND CENTURY GROUP INC (NYSE American), ACORDA THERAPEUTICS INC (NASDAQ), PALATIN TECHNOLOGIES INC (NYSE American), SUMMIT THERAPEUTICS PLC ADS EACH REPR 5 ORD (NASDAQ), IMUGENE LIMITED (ASX), OTONOMY INC (NASDAQ), AVEO PHARMACEUTICALS INC (NASDAQ), COHBAR INC (NASDAQ), BRAINSTROM CELL THERAPEUTICS (NASDAQ), STEALTH BIOTHERAPEUTICS CORP SPON ADS EACH REP 12 ORD SHS (NASDAQ), CHAMPIONS ONCOLOGY INC (NASDAQ), ORGENESIS INC (NASDAQ), SESEN BIO INC (NASDAQ), EQUILLIUM INC (NASDAQ), TREVENA INC (NASDAQ), PROTEOSTASIS THERAPEUTICS INC (NASDAQ), INFLARX N V (NASDAQ), SYNLOGIC INC (NASDAQ), ONCOLYTICS BIOTECH INC (NASDAQ), ANIXA BIOSCIENCES INC (NASDAQ), AXOVANT GENE THERAPIES LTD (NASDAQ), BELLICUM PHARMACEUTICALS (NASDAQ), SURFACE ONCOLOGY INC (NASDAQ), ASLAN PHARMACEUTICALS LIMITED ADS EACH REP 5 ORD SHS (NASDAQ), CATALYST BIOSCIENCES INC (NASDAQ), CYNATA THERAPEUTICS LTD (ASX), INFINITY PHARMACEUTICALS INC (NASDAQ), IMMUTEP LTD SPON ADS EACH REP 10 ORD SHS (NASDAQ), IMMUTEP LTD (ASX), VERMILLION INC (NASDAQ), TIZIANA LIFE SCIENCES PLC SPON ADS EACH REPR 10 ORD SHS (NASDAQ), ONCOSIL MEDICAL LIMITED (ASX), MICROBOT MEDICAL INC (NASDAQ), SYNTHETIC BIOLOGICS INC (NYSE American), CATABASIS PHARMACEUTICALS INC (NASDAQ), NEWLINK GENETICS CORP (NASDAQ), ENTASIS THERAPEUTICS HLDGS INC (NASDAQ), SOLIGENIX INC (NASDAQ), CO DIAGNOSTICS INC (NASDAQ), ORTHOCELL LIMITED (ASX), PLURISTEM THERAPEUTICS INC (NASDAQ), KEZAR LIFE SCIENCES INC (NASDAQ), VASCULAR BIOGENICS LTD (NASDAQ), GENOCEA BIOSCIENCES INC (NASDAQ), CT ENTERPRISE (HKEx), SUNESIS PHARMACEUTICALS INC (NASDAQ), ONCONOVA THERAPEUTICS INC (NASDAQ), ALPINE IMMUNE SCIENCES INC (NASDAQ), CURIS INC (NASDAQ), T2 BIOSYSTEMS INC (NASDAQ), INMUNE BIO INC (NASDAQ), IDERA PHARMACEUTICALS INC (NASDAQ), DIAMEDICA THERAPEUTICS INC (NASDAQ), OPIANT PHARMACEUTICALS INC (NASDAQ), RESTORBIO INC (NASDAQ), ISORAY INC (NYSE American), ADVAXIS INC (NASDAQ), MIRAGEN THERAPEUTICS INC (NASDAQ), CLEVELAND BIOLABS INC (NASDAQ), ORGANOVO HLDGS INC (NASDAQ), MERRIMACK PHARMACEUTICALS INC (NASDAQ), NEON THERAPEUTICS INC (NASDAQ), FORWARD PHARMA AS SPON ADS EACH REP 14 ORD SHS (NASDAQ), LEAP THERAPEUTICS INC (NASDAQ), AQUABOUNTY TECHNOLOGIES INC (NASDAQ), ZAFGEN INC (NASDAQ), EVOGENE LTD (NASDAQ), ITERUM THERAPEUTICS PLC (NASDAQ), CELLDEX THERAPEUTICS INC (NASDAQ), INVEX THERAPEUTICS LTD NPV (ASX), BIOSINO BIO-TEC (HKEx), BIOCARDIA INC (NASDAQ), ALIMERA SCIENCES INC (NASDAQ), HTG MOLECULAR DIAGNOSTICS INC (NASDAQ), BIOTRON (ASX), PULMATRIX INCORPORATED (NASDAQ), VISTAGEN THERAPEUTICS INC (NASDAQ), OCUGEN INC (NASDAQ), VAXART INC (NASDAQ), SEELOS THERAPEUTICS INC (NASDAQ), GENETIC TECHNOLOGIES (ASX), UNUM THERAPEUTICS INC (NASDAQ), KAZIA THERAPEUTICS LIMITED SPON ADR EACH REP 10 ORD SHS (NASDAQ), SOPHIRIS BIO INC (NASDAQ), MEREO BIOPHARMA GROUP PLC SPON ADS EACH REP 5 ORD SHS (NASDAQ), KAZIA THERAPEUTICS LIMITED (ASX), AEVI GENOMIC MEDIC (NASDAQ), INNOVATE BIOPHARMACEUTICALS INC (NASDAQ), BIONANO GENOMICS INC (NASDAQ), APTEVO THERAPEUTICS INC (NASDAQ), ACTINOGEN MEDICAL LTD (ASX), ARMATA PHARMACEUTICALS INC (NYSE American), REGENT PACIFIC (HKEx), AZURRX BIOPHARMA INC (NASDAQ), ANTEOTECH LIMITED (ASX), OUTLOOK THERAPEUTICS INC (NASDAQ), BIONOMICS LTD (ASX), MEMPHASYS LTD (ASX), TALI DIGITAL LIMITED (ASX), IBIO INC (NYSE American), DARE BIOSCIENCE INC (NASDAQ), CELLECTAR BIOSCIENCES INC (NASDAQ), ATYR PHARMA INC (NASDAQ), AETERNA ZENTARIS INC (NASDAQ), SIERRA ONCOLOGY INC (NASDAQ), EXTRAWELL PHAR (HKEx), CCP TECHNOLOGIES LTD (ASX), ORAGENICS INC (NYSE American), GENETIC TECHNOLOGIES SPON ADS EA REP 600 ORD SHS(R/S) (NASDAQ), RHINOMED LIMITED (ASX), INDIA GLOBALIZATION CAPITAL INC (NYSE American), BIO-PATH HOLDINGS INC (NASDAQ), ACTINIUM PHARMACEUTICALS INC (NYSE American), PROTEOMICS INTL LABORATORIES LTD (ASX), MIDATECH PHARMA PLC SPON ADS EACH REP 20 ORD SHS(R/S) (NASDAQ), CORREVIO PHARMA CORP (NASDAQ), IMMURON LIMITED (ASX), SELLAS LIFE SCIENCES GROUP INC (NASDAQ), TRACON PHARMACEUTICALS INC (NASDAQ), PRESCIENT THERAPEUTICS LIMITED (ASX), TROVAGENE INC (NASDAQ), PRECIPIO INC (NASDAQ), IMMURON LIMITED SPON ADR EACH REPR 40 ORD SHS (NASDAQ), CELLMID LIMITED (ASX), DIFFUSION PHARMACEUTICALS INC (NASDAQ), PATRYS LIMITED (ASX), ENDRA LIFE SCIENCES INC (NASDAQ), HEAT BIOLOGICS INC (NASDAQ), CONTANGO ASSET MANAGEMENT LIMITED (ASX), CYCLACEL PHARMA IN (NASDAQ), REGENEUS LTD (ASX), CONATUS PHARMACEUTICALS INC (NASDAQ), TOCAGEN INC (NASDAQ), BIOCEPT INC (NASDAQ), ADALTA LTD (ASX), ALTERITY THERAPEUTICS LIMITED (ASX), HOLISTA COLLTECH LIMITED (ASX), ALTERITY THERAPEUTICS LIMITED SPON ADS EA REPR 60 ORD SHS (NASDAQ), ACHIEVE LIFE SCIENCE INC (NASDAQ), ANATARA LIFESCIENCES LTD (ASX), SENESTECH INC (NASDAQ), SIENNA CANCER DIAGNOSTICS LTD (ASX), SENECA BIOPHARMA INC (NASDAQ), ANCHIANO THERAPEUTICS LTD SPON ADS EACH REP 5 ORD SHS (NASDAQ), NOVABAY PHARMACEUTICALS INC (NYSE American), OPGEN INC (NASDAQ), CAN FITE BIOPHARMA LTD SPON ADS EA REP 30 ORD SHS(POST REV SPL (NYSE American), NEUROSCIENTIFIC BIOPHARMA LTD (ASX), XENETIC BIOSCIENCES INC (NASDAQ), PLUS THERAPEUTICS INC (NASDAQ), AIM IMMUNOTECH INC (NYSE American), ARCA BIOPHARMA INC (NASDAQ), REXAHN PHARMACEUTICALS INC (NASDAQ), LIVING CELL TECHNOLOGIES (ASX), CELLECT BIOTECHNOLOGY LTD SPON ADS EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), BENITEC BIOPHARMA LTD SPON ADS EA REPR 200 ORD SHS(POST SPLIT) (NASDAQ), CAPRICOR THERAPEUTICS INC (NASDAQ), HAO WEN HLDGS (HKEx), BENITEC BIOPHARMA LTD (ASX), AUSTRALIAN PRIMARY HEMP LTD (ASX), BIOXYNE LIMITED (ASX), XTL BIOPHARMACEUTICALS LTD SPON ADS EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), MEDIBIO LIMITED (ASX), PHIO PHARMACEUTICALS CORP (NASDAQ), MGRC (Bursa), SPHERIX INC (NASDAQ), TBG DIAGNOSTICS LTD (ASX), AURIS MEDICAL HOLDING LTD (NASDAQ), INVIVO THERAPEUTICS HOLDING CORP (NASDAQ), AVECHO BIOTECHNOLOGY LTD (ASX), NANOLLOSE LTD (ASX), AMPLIA THERAPEUTICS LTD (ASX), THERAPIX BIOSCIENCES LTD SPON ADR EACH REP 40 ORD (POST SPLIT) (NASDAQ), BPH ENERGY LIMITED (ASX), FACTOR THERAPEUTICS LIMITED (ASX)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

Not enough data to show total shareholder returns
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 79.970 - 79.970 Change From 1 Year Low - % Change From 1 Year Low (%) -
Change From 1 Year High - % Change From 1 Year High (%) -
2 Years Range 79.970 - 79.970 Change From 2 Years Low - % Change From 2 Years Low (%) -
Change From 2 Years High - % Change From 2 Years High (%) -
5 Years Range 79.970 - 79.970 Change From 5 Years Low - % Change From 5 Years Low (%) -
Change From 5 Years High - % Change From 5 Years High (%) -
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

Lonza Group Ltd is a corporation incorporated under the laws of Switzerland and has been listed on the SIX Swiss Exchange (the “SIX”) since November 1999.Lonza is a supplier to the pharmaceutical, healthcare and life sciences industries with products and services spanning from research to final product manufacture to meet customers' needs. The products Lonza manufacture for the life sciences industry can be characterised as very complex molecules which are manufactured in a highly regulated environment and will end up in the body of human beings or animals.Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. The Group has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts which play an important role in the development of novel medicines and healthcare products. The Group provides cell-based research, endotoxin detection and cell therapy manufacturing. The Group is also a provider of high value chemicals and biotech ingredients to the nutrition, hygiene, preservation, agro and personal care markets.To provide optimal support to its customers, the Group is organized into three business divisions, namely, Custom Manufacturing, Life Science Ingredients and Bioscience, which focus on specific sets of customers and their needs.

IPO Performance

Listing Date 21 Oct 2011 Full Subscription Rate (x) -
No of Placement Shares (M) - No of Public Offer Shares (M) - Public Offer Subscription Rate (x) -
IPO Price (SGD) a - First Day Close (SGD) a 79.970 First Week Close (SGD) a 79.970
Current vs IPO Price (%) - First Day Gain (%) - First Week Gain (%) -
Notes:
  1. Adjusted for the following: IPO Price is not available as there are no issue of Shares under the Listing by way of Introduction.

Reports Download

Report Type Financial Year Ended Download
Annual Report
Annual Report 2018 Dec 2018 Part 1(3.19 MB)
Part 2(7.67 MB)
Annual Report 2017 Dec 2017 Part 1(10.98 MB)
Annual Report 2016 Dec 2016 Part 1(7.93 MB)
Annual Report 2015 Dec 2015 Part 1(1.90 MB)
Part 2(2.28 MB)
Annual Report 2014 Dec 2014 Part 1(3.90 MB)
Part 2(6.06 MB)
Annual Report 2013 Dec 2013 Part 1(3.42 MB)
Annual Report 2012 Dec 2012 Part 1(3.87 MB)
Annual Report 2011 Dec 2011 Part 1(5.01 MB)

Historical Price Data

Date Open High Low Close Volume VWAP
28 Jan 2020 79.970 79.970 79.970 79.970 - -
24 Jan 2020 79.970 79.970 79.970 79.970 - -
23 Jan 2020 79.970 79.970 79.970 79.970 - -
22 Jan 2020 79.970 79.970 79.970 79.970 - -
21 Jan 2020 79.970 79.970 79.970 79.970 - -
20 Jan 2020 79.970 79.970 79.970 79.970 - -
17 Jan 2020 79.970 79.970 79.970 79.970 - -
16 Jan 2020 79.970 79.970 79.970 79.970 - -
15 Jan 2020 79.970 79.970 79.970 79.970 - -
14 Jan 2020 79.970 79.970 79.970 79.970 - -
13 Jan 2020 79.970 79.970 79.970 79.970 - -
10 Jan 2020 79.970 79.970 79.970 79.970 - -
09 Jan 2020 79.970 79.970 79.970 79.970 - -
08 Jan 2020 79.970 79.970 79.970 79.970 - -
07 Jan 2020 79.970 79.970 79.970 79.970 - -
06 Jan 2020 79.970 79.970 79.970 79.970 - -
03 Jan 2020 79.970 79.970 79.970 79.970 - -
02 Jan 2020 79.970 79.970 79.970 79.970 - -
31 Dec 2019 79.970 79.970 79.970 79.970 - -
30 Dec 2019 79.970 79.970 79.970 79.970 - -
27 Dec 2019 79.970 79.970 79.970 79.970 - -
26 Dec 2019 79.970 79.970 79.970 79.970 - -
Summary
Current 2 Weeks
(14 Jan 2020 to 28 Jan 2020)
79.970 79.970 79.970 79.970 - -
Previous 2 Weeks
(30 Dec 2019 to 13 Jan 2020)
79.970 79.970 79.970 79.970 - -
4 Weeks from
(29 Nov 2019 to 27 Dec 2019)
79.970 79.970 79.970 79.970 - -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.